Clinical Trials Browser

INDUSTRY × Multiple Myeloma × ibrutinib × Clear all

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02902965 2020-03-16

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

74 enrolled 20 charts

Plasma cell

Multiple Myeloma

NCT01478581 2020-03-10

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

92 enrolled 21 charts

Plasma cell

Multiple Myeloma

NCT02548962 2019-11-21

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 12 charts

Plasma cell

Multiple Myeloma

Clinical Trials

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma